We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Somaxon Pharmaceuticals, Inc. (MM) | NASDAQ:SOMX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 0 | 01:00:00 |
From May 2019 to May 2024
DOW JONES NEWSWIRES
Somaxon Pharmaceuticals Inc. (SOMX) said it is suing Mylan Pharmaceuticals Inc. (MYL) for trying to market a generic version of its Silenor sleep medication.
The suit filed in the U.S. District Court for the District of Delaware claims Mylan's abbreviated new drug application infringes on Somaxon's patent, according to the company's filing with the Securities and Exchange Commission. In May, Somaxon filed a similar lawsuit against Par Pharmaceutical Inc. (PRX) over that firm's efforts to market its own generic version of Silenor.
Somaxon earlier last month said its first-quarter loss widened sharply on higher costs, though it reported product sales, of which it had none a year earlier.
Somaxon shares fell 6% to $2.05 after-hours Tuesday, after gaining about as much during the session. Mylan shares were unchanged at $23.75 after-hours.
-By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com
1 Year Somaxon Chart |
1 Month Somaxon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
